Charles E. Geyer, MD, discusses the FDA approvals of trastuzumab deruxtecan for the management of early-stage HER2-positive breast cancer.

Martin Schoen, MD, and Andrew W. Hahn, MD, discuss ARPI use in elderly, frail, and high-comorbidity patients with mCSPC.

In today’s episode, we welcomed Claire Harrison, MD, a professor of myeloproliferative neoplasms and clinical director at Guy's and St Thomas' NHS Foundation Trust in London, United Kingdom.In the exclusive interview, Dr Harrison discussed management strategies for anemia in patients with myelofibrosis and the implications of the phase 3 INDEPENDENCE trial (NCT04717414) presented at the 2026 EHA Congress. Dr Harrison detailed the prevalence and current challenges in managing myelofibrosis-associated anemia. She also detailed key efficacy outcomes reported for luspatercept-aamt (Reblozyl) in the INDEPENCENCE study, along with outlining some of the factors that contributed to the study narrowly missing statistical significance for its primary end point of red blood cell transfusion independence for at least 12 consecutive weeks during the first 24 weeks of treatment.

In this podcast, experts Philippe Moreau, MD; Suzanne Lentzsch, MD, PhD; and Shaji Kumar, MD, discuss therapeutic innovations in the treatment of multiple myeloma, including frontline quadruplet therapy, administration considerations for therapy, and optimal sequencing of CAR T-cell therapy, bispecific antibodies, and antibody-drug conjugates.To learn more about this topic, including information on future directions in MM and audience Q&A, go to https://www.gotoper.com/courses/medical-crossfire-turning-therapeutic-innovation-into-practicepersonalizing-care-in-multiple-myeloma-p2f5.This podcast, including the narration, was developed by PER® editorial staff based on an online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

Dr O’Malley discusses his approach to treatment selection and sequencing in platinum-resistant ovarian cancer.

Courtney D. DiNardo, MD, MSCE, discusses the FDA approval of decitabine and cedazuridine plus venetoclax for acute myeloid leukemia.

In this podcast, experts Kathleen N. Moore, MD, MS, FASCO; Ritu Salani, MD, MBA; Casey Cosgrove, MD; and Ebony R. Hoskins, MD, FACOG, discuss several cases of endometrial cancer using biomarkers to drive treatment decisions.

Zev A. Wainberg, MD, discusses the rapidly evolving landscape of KRAS-directed therapy in PDAC from pan-RAS inhibition to KRAS G12D–specific strategies.

Brad Haverkos, MD, discusses evolving management and treatment adherence strategies in cutaneous T-cell lymphoma.